louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03855839: The Effect of Posture Shirts on Posture During Functional Tasks
Official title: The Effect of Posture Shirts on Posture During Functional Tasks in Healthy Participants.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Healthy
Keywords: Posture
Muscle activity
Posture corrective shirts
Lead sponsor: University College of Northern Denmark
Sponsor class: OTHER
Collaborators: name: Aalborg University
First posted: 2019-02-27
Enrollment: 30
Sex: MALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Healthy male participants

Brief summary: This study investigates the effect of a posture shirt on posture during functional tasks such as office work.

Detailed description: Poor posture have historically been blamed for pain and disability in the general population. A treatment-strategy that have gain popularity in recent years is the use of a posture shirt which is a compressive shirt designed and marketed to the general public and health service providers as a way to improve posture and consequently alter muscle activity, reduce musculoskeletal pain and discomfort. This study will investigate the effect of posture shirts on posture.

Eligibility criteria: Inclusion Criteria: - Healthy participants

* Pain free healthy participants
* Able to speak, read and understand Danish Exclusion Criteria: - Healthy participants
* Pain from the back, neck or shoulder area during the past 3 months
* Any discomfort in relation to computer use
* Lack of ability to cooperate

Primary outcomes:
measure: Posture
timeFrame: Within session (2hr)
Secondary outcomes:
measure: Experienced pain
timeFrame: Within session (2hr)
measure: Concentration during task
timeFrame: Within session (2hr)
measure: Consciousness of posture during task
timeFrame: Within session (2hr)
Other outcomes:
Locations:
city: Aalborg
country: Denmark
facility: Department of Physiotherapy, University College of Northern Denmark
Study officials:
affiliation: Department of Physiotherapy, University College of Northern Denmark
name: Steffan W Christensen, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03818139: Performance of Lung Ultrasonography for Endotracheal Tube Positioning in Neonates
Official title: Performance of Lung Ultrasonography for Endotracheal Tube Positioning in Neonates
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Diagnostic Imaging
Newborn
Intubation
Ultrasonography
Keywords: diagnostic imaging, Newborn, Intubation, Ultrasonography methods
Lead sponsor: University Hospital, Limoges
Sponsor class: OTHER
First posted: 2019-01-28
Enrollment: 55
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Newborns treated with mechanical ventilation and required chest X ray for determining ETT position

Brief summary: Lung Ultrasonography (US) has been shown to be effective for verifying endotracheal tube (ETT) position in adults and children but has been less studied in neonates. The aim of this study is to evaluate the performance of lung US in determining correct ETT position in neonates, in comparison with X Ray


Eligibility criteria: Inclusion Criteria:

* Newborns
* treated with mechanical ventilation
* and required chest X ray for determining ETT position
* hospitalised in neonatal intensive Care unit , Limoges, France
* signed parental inform consent

Exclusion Criteria:

* Congenital heart disease

Primary outcomes:
measure: Concordance of ETT positioning according to lung ultrasonography with chest X ray results
timeFrame: Day 0
Secondary outcomes:
measure: time of realization lung US
timeFrame: Day 0
measure: time of realization chest X ray
timeFrame: Day 0
measure: variability inter observator
timeFrame: Day 0
Other outcomes:
Locations:
city: Limoges
country: France
facility: University Hospital, Limoges
Study officials:
References:
Clinical trial NCT04556539: Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian Cancer
Official title: SC10914 Monotherapy for gBRCA1/2 Mutation Advanced Ovarian Cancer Patients With at Least 2 Prior Lines of Chemotherapy: a Single Arm, Open Label, Multicenter Clinical Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Advanced Ovarian Cancer
Lead sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Sponsor class: INDUSTRY
First posted: 2020-09-21
Enrollment: 104
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A phase II, multicenter, open-label, single-arm study to evaluate the efficacy, safety and pharmacokinetics of SC10914 in subjects with gBRCA1/2 mutated advanced ovarian cancer in china.

Detailed description: A total of 104 subjects with gBRCA1/2 mutated advanced ovarian cancer is planned to be enrolled to observe the efficacy, safety and PK profile of SC10914.

The subjects oral administration SC10914 tablets 400mg on an empty stomach, three times a day, for 28 consecutive days as a treatment cycle, until disease progression (PD) or the toxicity was intolerable. PK blood samples are planned to be collected for each enrolled subject on C1D28 visit.

Eligibility criteria: Inclusion Criteria:

1. Sign informed consent voluntarily;
2. ≥18 years old;
3. Histologically confirmed ovarian epithelial cancer, fallopian tube cancer or primary peritoneal cancer( high-grade carcinoma cancer or endometrioid carcinoma);
4. gBRCA1/2 mutation positive;
5. Had recived at least 2 prior lines of chemotherapy;
6. Platinum sensitive patients;
7. The last line of therapy befor enrollment failed；
8. ECOG≤2；

8. Had at least one measurable lesion.

Exclusion Criteria:

1. Any previous treatment with PARP inhibitor;
2. Symptomatic brain metastases;
3. Large amount of fluid in the third gap；
4. Subjects with not enough organ functional reserve at baseline, which met at least one of the following criteria： ANC\<1.5×10\^9/L PLT\<100×10\^9/L Hb\<100g/L TBIL\>1.5×ULN ALT, AST\>2.5×ULN (without liver metastases) or ALT, AST\>5×ULN (with liver metastases) Cr \>1.5×ULN

Primary outcomes:
measure: objective response rate (ORR)
timeFrame: up to 100 weeks (estimated)
Secondary outcomes:
Other outcomes:
Locations:
city: Fujian
country: China
facility: Fujian Cancer Hospital
Study officials:
References:
Clinical trial NCT01548339: Laparoscopic Cholecystectomy for Acute Cholecystitis After 72 Hours of Symptoms
Official title: Laparoscopic Cholecystectomy for Acute Cholecystitis: is the Rule of 72 Hours Still Actual?
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Acute Cholecystitis
Cholecystectomy
Lead sponsor: University of Lausanne Hospitals
Sponsor class: OTHER
First posted: 2012-03-08
Enrollment: 86
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare the clinical outcomes of early versus delayed laparoscopic cholecystectomies for acute cholecystitis with more than 72 hours of symptoms.

Detailed description: In acute biliary cholecystitis, there was a dogma that patients should be operated within 72 hours of evolution. However, retrospective studies suggested that laparoscopic cholecystectomy even after 72 hours was safe. Moreover, some randomized controlled-trials did not found any differences in term of complications between early and delayed cholecystectomy, however none of these studies did separate patients according to the onset of symptoms. The aim of our present study was to compare the clinical outcomes of immediate versus delayed cholecystectomies for acute cholecystitis with more than 72 hours of symptoms.

Eligibility criteria: Inclusion Criteria:

* proven echographic cholecystitis

Exclusion Criteria:

* pregnancy
* immunosuppression
* severe sepsis
* perforated cholecystitis
* peritonitis
* cholangitis
* acute pancreatitis

Primary outcomes:
measure: Number of Participants With Adverse Event ("Global Morbidity").
timeFrame: 30 postoperative days
Secondary outcomes:
measure: Postoperative Complications
timeFrame: 30 postoperative days
measure: Length of Stay
timeFrame: 30 postoperative days
Other outcomes:
Locations:
city: Lausanne
country: Switzerland
facility: University of Lausanne Hospitals
state: Vaud
Study officials:
affiliation: University of Lausanne Hospitals
name: Nicolas Demartines, MD
role: STUDY_CHAIR
affiliation: University of Lausanne Hospitals
name: Nermin Halkic, MD
role: STUDY_DIRECTOR
affiliation: University of Lausanne Hospitals
name: Luca Di Mare, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Roulin D, Saadi A, Di Mare L, Demartines N, Halkic N. Early Versus Delayed Cholecystectomy for Acute Cholecystitis, Are the 72 hours Still the Rule?: A Randomized Trial. Ann Surg. 2016 Nov;264(5):717-722. doi: 10.1097/SLA.0000000000001886.
Clinical trial NCT00422539: Efficacy of TCA Effect on Varicella Atrophic Scars
Official title: Evaluation of Tri Chloro Acetic Acid (TCA) Effect on Atrophic Varicella Scars
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Atrophic Varicella Scar
Keywords: trichloroacetic acid
varicella scar
Lead sponsor: Shahid Beheshti University of Medical Sciences
Sponsor class: OTHER
First posted: 2007-01-17
Enrollment: 100
Sex: ALL
Minimum age (years): 15
Maximum age (years): 45
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study aims to determine the efficacy of 70% trichloroacetic acid on atrophic scars of varicella

Detailed description: high concentration trichloroacetic acid peeling has been shown to be effective in treating and flattening the atrophic acne scars. According to the lack of an effective and low cost therapy for removing these relative common and nuisance lesions; We aimed to answer that whether we could achieve the same results from 70% TCA on atrophic varicella scars.

Eligibility criteria: Inclusion Criteria:

* Atrophic varicella scar on face

Exclusion Criteria:

* Active varicella infection
* Active Herpetic infection
* Previous history of keloid formation

Primary outcomes:
measure: Objective Clearance(before and after photographies were taken)
Secondary outcomes:
measure: Subjective Clearance(according to the patients satisfaction)
measure: Adverse effects(assessed by clinician as erythema, pigmentary changes, scaring)
Other outcomes:
Locations:
city: Tehran
country: Iran, Islamic Republic of
facility: Skin Research Center, Shohada-e Tajrish Hospital, shaheed Beheshti Medical University
Study officials:
affiliation: Skin Research Center of Shaheed Beheshti medical University
name: Parviz Toossi, M.D.
role: STUDY_CHAIR
affiliation: Skin Research Center of Shaheed Beheshti Medical Universty
name: Behrooz Barikbin, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT07022639: Influence of Hospital Volume on Mortality and Length of Hospital Stay After Pancreatic Resection in Switzerland
Official title: Influence of Hospital Volume on Mortality and Length of Hospital Stay After Pancreatic Resection in Switzerland: A Retrospective National Registry Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pancreatic Diseases
Lead sponsor: Cantonal Hospital of St. Gallen
Sponsor class: OTHER
First posted: 2025-06-15
Enrollment: 6785
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients with pancreatic resection in Switzerland between 2013 and 2022.

Brief summary: The effect of centralisation measures on the operative outcomes after pancreatic resection in Switzerland has not been highlighted yet. This study aims to investigate the influence of the annual hospital specific case load of pancreatic resection on short-term postoperative outcomes.


Eligibility criteria: Inclusion Criteria:

* All patients with pancreatic resection in Switzerland between 2013 and 2022

Exclusion Criteria:

* incomplete case documentation
* age under 20 years
* other hospitals than general or surgical hospitals
* no index operation

Primary outcomes:
measure: Mortality
timeFrame: Periprocedural
Secondary outcomes:
measure: Reoperation
timeFrame: Periprocedural
measure: Length of hospital stay
timeFrame: Periprocedural
measure: Sociodemographic trends
timeFrame: 2013 - 2022
Other outcomes:
Locations:
city: St.Gallen
country: Switzerland
facility: HOCH Health Ostschweiz, Kantonsspital St.Gallen
Study officials:
References:
Clinical trial NCT05102539: Causes of Non-invasive Fungal Sinusitis as Presented in Sohag University Hospital
Official title: Epidemiological Study of Non-invasive Fungal Sinusitis as Presented in Sohag University Hospital
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Sinus Infection
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2021-11-01
Enrollment: 70
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Non-invasive Fungal Sinusitis patients as Presented in Sohag University Hospital

Brief summary: in this study, the investigators will collect data from patients with non-invasive fungal sinusitis to know what causes it

Detailed description: In this study, the investigators will try to know the epidemiology of noninvasive fungal sinusitis, especially in recurrent cases This study will be carried out at sohag university hospital. Retrospective study Study period: 5 years (from August 2016 to August 2021. )

Eligibility criteria: Inclusion Criteria:

* Patients with Acute fungal sinusitis.
* Patients with chronic granulomatous sinusitis.
* Patients with sinus mycetomas.

Exclusion Criteria:

* Immunocompromised patients.
* invasive fungal sinusitis.

Primary outcomes:
measure: risk factors related to non-invasive fungal sinusitis
timeFrame: 5 years study period from august 2016 to august 2021
Secondary outcomes:
Other outcomes:
Locations:
city: Sohag
country: Egypt
facility: Sohag University Hospital
Study officials:
References:
Clinical trial NCT03347539: Implants on Mobile Health Unit
Official title: Adolescent Uptake of Implants on a Mobile Health Unit
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Contraception
Lead sponsor: University of Chicago
Sponsor class: OTHER
First posted: 2017-11-20
Enrollment: 1
Sex: FEMALE
Minimum age (years): 14
Maximum age (years): 19
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study population will be adolescent females seeking reproductive healthcare on a mobile health unit.

Brief summary: This study explores reasons why adolescents choose to receive a nexplanon implant and remove a Nexplanon implant. Nexplanon is provided as part of the standard of care on the University of Chicago mobile health unit. This study explores reasons for implantation and removal of Nexplanon on this mobile health unit.


Eligibility criteria: Inclusion Criteria:

* Be biologically female
* Be seeking reproductive healthcare on a mobile health unit
* Be interested in receiving Nexplanon for birth control.
* Be between 14 and 19 years of age.

Exclusion Criteria:

* Be biologically male
* Be 13 and younger or 20 and older.

Primary outcomes:
measure: Reasons for choosing Nexplanon
timeFrame: One time, immediately before receiving implant.
Secondary outcomes:
measure: Reasons for choosing to remove Nexplanon
timeFrame: One time, immediately before removing implant.
Other outcomes:
Locations:
city: Chicago
country: United States
facility: The University of Chicago Medicine
state: Illinois
Study officials:
References:
Clinical trial NCT00440739: Etoricoxib With Flavoxate for Reducing Morphine Requirement After Transurethral Prostatectomy (TURP)
Official title: Etoricoxib With Flavoxate for Reducing Morphine Requirement After Transurethral Prostatectomy: A Factorial Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Pain
Keywords: postoperative pain, etoticoxib, etoricoxib
Pain relief after transurethral resection of prostate.
Lead sponsor: Mahidol University
Sponsor class: OTHER
First posted: 2007-02-27
Enrollment: 128
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether etoricoxib, flavoxate, both are effective in the treatment postoperative pain after TURP.

The research hypothesis:

There is a difference in postoperative morphine consumption in the first 24 hours after transurethral prostatectomy between patients who received etoricoxib or flavoxate or both and placebo.

Detailed description: Postoperative pain is still a significant problem for surgical patients. Conventional use of narcotics for postoperative pain relief is not without serious side effects such as respiratory depression and sedation.There are other alternatives for postoperative analgesia as NSAIDs especially COX2-inhibitors. For some specific operation such as TURP which Foley's catheter needed to be retained for a few days,urinary anti spasmodics may help the patients to be more comfortable.

Comparison(s): There is a difference in postoperative morphine consumption in the first 24 hours after transurethral prostatectomy between patients who received etoricoxib or flavoxate or both and placebo.

Eligibility criteria: Inclusion Criteria:

1. Male patient ASA physical status I-III.
2. Scheduled for an elective TURP.
3. Body weight \> or = 50 kg
4. Can operate a patient-controlled analgesia (PCA) device.

Exclusion Criteria:

1. History of asthma, acute rhinitis, nasal polyps, angioneurotic edema or urticaria following the administration of aspirin or other NSAIDs.
2. Known hypersensitivity to morphine.
3. History of hepatic dysfunction.
4. Creatinine clearance \< 30ml/min.
5. History of bleeding tendency.
6. History of gastrointestinal bleeding or active peptic ulcer.
7. Known case of inflammatory bowel disease.
8. Patient with severe heart failure.
9. History of coronary artery disease or cerebrovascular disease.

Primary outcomes:
measure: The patients' total amount of morphine requirement in the first 24 hour.
timeFrame: 24 hour
Secondary outcomes:
Other outcomes:
Locations:
city: Bangkok
country: Thailand
facility: Faculty of Medicine Siriraj Hospital, Mahidol University
Study officials:
affiliation: Department of Anesthesiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand
name: Sirilak Suksompong, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02359539: Marginal Periosteal Pedicle Flap - Platelet Rich Fibrin Barriers in Treating Periodontal Intrabony Defects
Official title: Marginal Periosteal Pedicle Flap and Platelet Rich Fibrin Barriers for the Treatment of Periodontal Intrabony Defects -Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Periodontal Pocket
Lead sponsor: Al-Azhar University
Sponsor class: OTHER
First posted: 2015-02-10
Enrollment: 10
Sex: ALL
Minimum age (years): 20
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The use of autogenous graft materials has been recorded to be a gold standard in regenerative therapy. This study directed toward evaluation of two autogenous regenerative materials, marginal periosteal pedicle graft (MPP) and platelet rich fibrin (PRF) as membrane barriers for treating intrabony defects. In spite of its reported significant clinical outcomes, the limited availability of the periosteum makes it necessary to evaluate other autogenous alternatives such as PRF that could offer predictable outcomes.

Detailed description: Material and methods: 10 patients with sever chronic periodontitis and at least single ≥4 mm intrabony defect had participated in this randomized clinical study. Subjects were randomly divided into2 groups, Group 1(MPP) defect coverage with xenograft defect fill(10 patients),Group 2(PRF) defect coverage with xenograft defect fill(10 patients).Clinical and radiographic measurements were carried out at 3,6 and 9 months postoperatively.

Eligibility criteria: Inclusion Criteria:

* No systemic diseases that could influence the outcome of therapy
* Good compliance for plaque control instructions after initial therapy
* Vital teeth
* Had contralateral matched pair of 2- or 3-walled intrabony interproximal defects in premolar or molar teeth
* Probing pocket depth (PPD)≥6 mm and clinical attachment level (CAL) ≥4mm 6) selected 2- or 3-wall intrabony defect depth ≥ 3 mm as detected in diagnostic periapical radiographs,

Exclusion Criteria:

* Pregnant females and patients presented with opened interproximal contact

Primary outcomes:
measure: Intrabony defect
timeFrame: 9 month after surgery
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: